An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)
- Conditions
- Thyroid Eye Disease
- Interventions
- Drug: Veligrotug (VRDN-001)Drug: Placebo
- Registration Number
- NCT06021054
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Brief Summary
A randomized, double-masked, placebo-controlled safety, tolerability and efficacy study of VRDN-001 in participants with chronic thyroid eye disease (TED)
- Detailed Description
A randomized, double-masked, placebo-controlled safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with chronic thyroid eye disease (TED)
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 159
- Must have moderate to severe chronic TED with documented evidence of ocular symptoms or signs that began greater than 15 months prior to screening
- Must have had a clinical diagnosis of TED, with any CAS (0-7)
- Must agree to use highly effective contraception as specified in the protocol
- Female TED participants must have a negative serum pregnancy test at screening
Key
- Must not have received prior treatment with another anti-IGF-1R therapy
- Must not have received systemic corticosteroids for any condition, including TED, or selenium within 2 weeks prior to first dose
- Must not have received other immunosuppressive drugs or another investigational agent for any condition, including TED, or any other therapy for TED, within 8 weeks prior to first dose
- Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose
- Must not have a pre-existing ophthalmic condition in the study eye that in the opinion of the study doctor would confound interpretation of the study results
- Must not have had previous orbital irradiation or decompression surgery for TED to the study eye's orbit
- Must not have a history of inflammatory bowel disease
- Must not have an abnormal hearing test before first dose or history of ear conditions considered clinically significant by the study doctor
- Female TED participants must not be pregnant or lactating
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Veligrotug (VRDN-001)10 mg/kg Veligrotug (VRDN-001) Drug: 5 IV Infusions of veligrotug (VRDN-001)10 mg/kg Placebo Drug Placebo Placebo Drug: 5 IV Infusions of placebo
- Primary Outcome Measures
Name Time Method Proptosis Responder Rate in the most proptotic eye Week 15 Proptosis Responder Rate in the most proptotic eye (i.e., reduction of proptosis of ≥2 mm from baseline \[without a corresponding increase of ≥2 mm in the other eye\])
- Secondary Outcome Measures
Name Time Method Change from baseline in proptosis in the most proptotic eye Week 15 Change from baseline in proptosis in the most proptotic eye
Clinical Activity Responder Rate in the most proptotic eye Week 15 Clinical Activity Responder Rate in the most proptotic eye (i.e., no worsening in CAS from baseline \[without a corresponding increase of ≥2 points in the other eye\])
Overall Responder Rate in the most proptotic eye Week 15 Overall Responder Rate (comprised of Proptosis Responder Rate and Clinical Activity Responder Rate) in the most proptotic eye
Diplopia Responder Rate Week 15 Diplopia Responder Rate (i.e., reduction in Gorman Subjective Diplopia Score of ≥1 from baseline for participants with baseline Gorman Subjective Diplopia Score)
Diplopia Resolution Rate Week 15 Diplopia Resolution Rate (i.e., reduction in Gorman Subjective Diplopia Score to 0 from baseline for participants with baseline Gorman Subjective Diplopia Score greater than 0)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (57)
Advancing Research International, LLC
🇺🇸Los Angeles, California, United States
USC Roski Eye Institute
🇺🇸Los Angeles, California, United States
Amy Patel Jain, MD
🇺🇸Newport Beach, California, United States
Stanford Byers Eye Institute
🇺🇸Palo Alto, California, United States
Cockerham Eye Consultants, PC
🇺🇸San Diego, California, United States
Bascom Palmer Eye Institute - Ophthalmology - Miami
🇺🇸Miami, Florida, United States
Sarasota Retina Institute
🇺🇸Sarasota, Florida, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
Family Eye Physicians, Ltd
🇺🇸Oak Lawn, Illinois, United States
Massachusetts Eye and Ear
🇺🇸Boston, Massachusetts, United States
Scroll for more (47 remaining)Advancing Research International, LLC🇺🇸Los Angeles, California, United States